Details of the planned presentations are listed below:
Revolution Medicines Oral Presentations:
Title: | Discovery of RMC-9805, an Oral, RAS(ON) G12D-Selective Covalent Tri-Complex Inhibitor |
Presenter: | |
Abstract Number: | ND03 |
Session: | New Drugs on the Horizon: Part 1 |
Date/Time: | 1:45 – |
Title: | RMC-6236, a RAS(ON) Multi-Selective Tri-Complex Inhibitor |
Presenter: | |
Session: | KRAS: Broadening the Attack Beyond G12C with Small Molecules and Immuno-Oncology |
Date/Time: | 1:00 – |
Title: | Combination of RAS(ON) G12C-Selective and Multi-Selective Tri-Complex Inhibitors Overcomes Resistance and Prolongs Durability in Preclinical Models of KRASG12C NSCLC |
Presenter: | |
Abstract Number: | 6585 |
Session: | Novel Antitumor Agents 5 |
Date/Time: | 2:35 – |
Revolution Medicines Poster Presentations:
Title: | Potential Biomarkers of Response to the Combination of the RAS(ON) Multi-Selective Inhibitor RMC-6236 Plus Anti-PD-1 Antibody in Preclinical PDAC Models |
Presenter: | |
Abstract Number: | 581/4 |
Session: | Immunotherapy |
Date/Time: | 1:30 – |
Title: | RMC-5127, a First-in-Class, Orally Bioavailable RAS(ON) G12V-Selective Tri-Complex Inhibitor, is CNS-Penetrant and Drives Regressions in Intracranially Implanted KRASG12V Xenograft Tumors |
Presenter: | |
Abstract Number: | 3340/28 |
Session: | Novel Antitumor Agents 3 |
Date/Time: | 1:30 – |
Title: | The RAS(ON) Multi-Selective Inhibitor RMC-7977 Blocks Downstream MAPK and PI3K Pathway Activation in KRASG12X-Mutant Cancers |
Presenter: | |
Abstract Number: | 4709/2 |
Session: | Other Cellular Mechanisms for Anticancer Drug Action |
Date/Time: | |
Collaborator Poster Presentations:
Title: | RTK Signaling and WT RAS Activity as Vulnerabilities in Tumors with Acquired Resistance to GDP-State Selective KRASG12C Inhibitors in Preclinical Models |
Lead RevMed Co-Author: | |
Abstract Number: | 1924/2 |
Session: | Drug Resistance 2: RAS GTPase |
Date/Time: | |
Title: | Resistance to RAS-GTP Inhibition in Models of Pancreatic Ductal Adenocarcinoma Arises Downstream of RAS Effectors |
Lead RevMed Co-Author: | |
Abstract Number: | 1927/5 |
Session: | Drug Resistance 2: RAS GTPase |
Date/Time: | |
Additional information on the AACR Annual Meeting 2024 is available through the AACR website at: https://www.aacr.org/meeting/aacr-annual-meeting-2024/
About
Media & Investor ContactErin Graves 650-779-0136 egraves@revmed.com
Source:
2024 GlobeNewswire, Inc., source